Literature DB >> 11049903

Part I: propofol, thiopental, sevoflurane, and isoflurane-A randomized, controlled trial of effectiveness.

P S Myles1, J O Hunt, H Fletcher, J Smart, T Jackson.   

Abstract

UNLABELLED: When compared with thiopental and isoflurane, propofol and sevoflurane are associated with a faster return to wakefulness after anesthesia. Yet their wider usage in inpatient surgery has been restrained by concerns regarding their acquisition costs and by lack of studies demonstrating improved patient outcome. We randomly allocated 453 adult surgical inpatients to one of four anesthetic regimens (thiopental-isoflurane, propofol-isoflurane, propofol induction and maintenance, or sevoflurane induction and maintenance) and measured their rate and quality of recovery. We found no significant differences in the rate and quality of recovery between groups. Propofol was associated with more pain on injection (P: < 0. 0005), but less cough during induction (P: = 0.003), and less early postoperative nausea and vomiting (P: = 0.003). We could not detect any significant advantages with propofol and sevoflurane, when compared with thiopental and isoflurane in adults undergoing elective inpatient surgery. IMPLICATIONS: Propofol and sevoflurane do not offer any significant advantages over thiopental and isoflurane in adults undergoing elective inpatient surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049903     DOI: 10.1097/00000539-200011000-00023

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Sex differences in speed of emergence and quality of recovery after anaesthesia: cohort study.

Authors:  P S Myles; A D McLeod; J O Hunt; H Fletcher
Journal:  BMJ       Date:  2001-03-24

Review 2.  Induction of anaesthesia: a guide to drug choice.

Authors:  Nathalie Nathan; Isabelle Odin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Total intravenous anaesthesia: is it worth the cost?

Authors:  Ian Smith
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.